Nkarta goes back to basics

Nkarta, like its competitor Fate Therapeutics, found an initial NK cell therapy breakthrough to have been short-lived. And today the company lifted the lid on the disappointment that had prompted it to go back to the drawing board, redesigning its chemo conditioning regimen to give a product that, it hopes, will be more efficacious and longer-lasting.